Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

13 Further functional imaging including somatostatin ... Association of VHL genotype with pancreatic neuroendocrine tumor phenotype in patients with von Hippel-Lindau disease.

BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) are uncommon and heterogeneous neoplasms, often exhibiting indolent biological behavior. Their incidence is rising, largely due to the widespread ...

Other functional abilities may remain intact ... The first, Lutathera, can be used to treat neuroendocrine tumors of the pancreas when the disease has spread in the body. The other drug is ...

“New therapeutic options are needed for patients with advanced NETs,” Jonathan Strosberg, MD, leader of the Neuroendocrine Tumor Division ... performance score of 1 (60% vs 50%), had a functional ...

found significant differences in the miRNA expression profiles of paragangliomas and pancreatic neuroendocrine tumors ... the upper cut-offs of reference intervals and “non-functional” tumors are ...

Effect of marital status and race on survival of patients with well differentiated neuroendocrine tumors (NETs). Clinicopathological factors related to survival in gastroenteropancreatic ...

Neuroendocrine ... in the pancreas. They can also rarely start in other organs of the body such as the bowel, lungs and liver. It’s a worrying time for many people and we want to be there for you ...